Current Project Portfolio
AIM Featured Partnerships
Mitobridge is discovering and developing small molecule therapeutics that enhance mitochondrial function and that build upon the emerging scientific findings linking mitochondrial dysfunction with disease pathologies.
Oct 7, 2013 Astellas and Mitobridge entered into an exclusive R&D collaboration focused on discovering and developing novel drugs that improve mitochondrial functions.
Nov 30, 2017 Astellas exercised its exclusive option right to acquire Mitobridge.
Pontenza Therapeutics, Inc. is a clinical-stage biotechnology company focused on building a portfolio of oncology programs that utilize the body's own immune system to seek out, recognize and destroy tumors through a diversity of mechanisms that influence tumor immunity. Apr 21, 2015 Astellas and Potenza, a biotechnology company developing a portfolio of immuno-oncology programs, announced an exclusive reseach and development collaboration.
Dec 13, 2018 Astellas exercised its exclusive option right to acquire Potenza.
Auration Biotech is a privately held biotechnology company dedicated to the development of novel therapeutics that restore or maintain hearing.
Jan 31, 2017 Astellas executed License Agreement with Auration Biotech for the development and commercialization of AU-935.
Pandion Therapeutics is developing modular biologics for autoimmune regulation that are designed to achieve lasting therapeutic outcomes for patients with autoimmune and inflammatory diseases.
Oct 31, 2019 Astellas and Pandion announced the signing of a License and Collaboration Agreement directed toward the research, development, and commercialization of locally acting immunomodulators for autoimmune diseases of the pancreas.